肠易激综合征数字疗法的开发与现状
本文综述了肠易激综合征(IBS)的病理生理、疾病负担、未满足的治疗需求,以及新型数字疗法(提供认知行为治疗和肠道导向催眠治疗)的证据基础。检索文献显示,临床试验数据支持用于自我引导认知行为治疗和催眠治疗的数字化治疗设备的开发和效用。脑-肠行为治疗(BGBT)是IBS有效且指南推荐的治疗方法,数字治疗设备为提供辅助性BGBT提供了可及、经济有效的选择。
要点
- 当前指南推荐脑-肠行为治疗(BGBT)联合其他IBS疗法,随机对照试验显示其可改善症状、满意度、功能和生活质量。
- BGBT的可及性受限于缺乏训练有素的胃肠心理学家、患者时间限制和费用。
- 临床试验数据支持数字疗法用于自我引导认知行为治疗和催眠治疗IBS。
核心结论
- BGBT是IBS有效且指南推荐的治疗方法;数字治疗设备为提供辅助性BGBT提供了可及、经济有效的选择。
- 推荐数字BGBT的决定应基于仔细的患者评估,包括心理健康筛查和风险评估。
研究设计与样本
- 本文为综述,检索了关于新型数字疗法提供认知行为治疗和肠道导向催眠治疗IBS的已发表文献。
主要发现
- 临床试验数据支持旨在提供自我引导认知行为治疗和催眠治疗的数字疗法的开发和效用。
- 当前药物治疗常不能完全缓解症状且可能耐受性差;胃肠道症状缓解不一定转化为生活质量改善。
- BGBT的可及性受限于缺乏训练有素的胃肠心理学家、患者时间限制和费用。
关键数值与推荐
- 当前指南推荐脑-肠行为治疗(BGBT)联合其他IBS疗法。
- 在随机对照试验中,BGBT已显示可改善症状、患者满意度、功能和生活质量。
临床怎么用
- 推荐数字BGBT的决定应基于仔细的患者评估,包括心理健康筛查和风险评估(作者建议)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Irritable bowel syndrome (IBS) is a common, debilitating disorder characterized by abdominal pain and disordered bowel habits. Current pharmacologic treatments often provide incomplete symptom relief and may be poorly tolerated. Furthermore, alleviation of gastrointestinal symptoms does not always translate into improved quality of life for IBS patients. Current treatment guidelines recommend brain-gut behavior therapy (BGBT) in conjunction with other IBS therapies, and, in randomized controlled trials, BGBT has been shown to improve symptoms, patient satisfaction, functioning, and quality of life. Access to BGBT is limited by lack of adequately trained gastrointestinal psychologists, patient time constraints, and cost. Furthermore, clinician knowledge that BGBT is specific, and different from psychotherapy approaches for common mental health disorders, may limit referrals even where available. This review provides an overview of the pathophysiology of IBS, disease burden, unmet therapeutic needs, evidence base of novel digital therapeutics for IBS, and guidance on the introduction and appropriateness of these interventions for patients. METHODS: We searched the literature for available published data relating to the use of novel digital therapeutics to provide cognitive behavioral therapy and gut-directed hypnotherapy in the treatment of irritable bowel syndrome. RESULTS: Clinical trial data support the development and utility of digital therapeutics designed to deliver self-guided cognitive behavioral therapy and hypnotherapy for the treatment of IBS. CONCLUSIONS: BGBTs are effective, guideline-recommended treatments for IBS. Digital therapeutic devices offer accessible, cost-effective treatment options for delivery of adjunctive BGBT for the treatment of IBS. The decision to recommend digital BGBTs should be guided by careful patient assessment that includes mental health screening and risk assessment.
引用
- Brenner DM, Ladewski AM, Kinsinger SW, et al. Development and Current State of Digital Therapeutics for Irritable Bowel Syndrome. Clin Gastroenterol Hepatol. 2023. PMID: 37743035. doi:10.1016/j.cgh.2023.09.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。